CA-RECOVER
10.12.2020 14:02:12 CET | Business Wire | Press release
Recover™ , a leading material sciences company and producer of sustainable, premium recycled cotton fiber and cotton fiber blends, through a strategic partnership with STORY3 Capital, is expanding to meet the surging demand from the global fashion industry. This strategic partnership will accelerate Recover’s efforts to transform the fashion industry by solving one of the world’s biggest environmental issues. STORY3 Capital brings significant investment, resources, and best-in-class operators to achieve Recover’s growth initiatives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005187/en/
The adverse environmental impact of the fashion industry is staggering, and the industry is lagging behind its climate action commitments and Sustainable Development Goals (SDGs). Cotton is one of the most damaging crops grown on earth, requiring large amounts of water, pesticides, and land. As an example, one t-shirt requires 2,700 liters of water, equivalent to what an average person drinks in three years(1) .
Recover recycles industrial and pre- and post-consumer cotton waste, replacing the need to cultivate cotton, limiting the use of dyes through its ColorBlend system, and reducing textile landfill waste. Through its proprietary technology using a combination of art and science, Recover provides cost competitive, maximum performance fibers for both rotor and ring spinning applications. Per the Higg Material Sustainability Index, Recover’s recycled cotton fiber has the lowest environmental impact score in the world.
As a result of the investment, Recover will increase its production to 200,000 metric tons of recycled cotton fiber per year by 2025. This will save nearly three trillion liters of water each year, equivalent to the drinking water consumed by 3 billion people on an annual basis, and allow 500,000 acres of land to be directed away from cotton cultivation for other uses.
Peter Comisar, Founder and CEO of STORY3 Capital and former Partner at Goldman Sachs & Co. said, “Recover is uniquely positioned to be the global sustainability leader in cotton recycling by acting as an agent of change within the industry, and quickly becoming the gold standard in closing the loop on fashion.” Ben Malka, Operating Partner at STORY3 Capital and Executive Chairman of Recover stated, “We immediately saw the potential to impact the pent-up demand for recycled cotton by scaling production and working with the industry to innovate and migrate to Recover Fibers.”
Recover is part of a fourth-generation family-owned company with a 70-year long history in textile recycling technology. Under the leadership of the Ferre family, Recover has specialized in creating premium recycled cotton fiber from textile waste using proprietary technology and innovative mechanical recycling machinery. The fiber is ultimately spun into yarn by supply chain partners and transformed into finished apparel garments and home textiles. Recover has supplied its recycled cotton and cotton blend fibers to illustrious brands such as Wrangler, H&M Group, Tommy Hilfiger, G-Star, The Northface, Billabong and Bonobo among many others during its rich history.
“My family has been innovating for generations to perfect the Recover process, which is primed to be fashion industry’s biggest resource in meeting its sustainability goals,” said Alfredo Ferre, CEO of Recover. “We’re proud to offer potential partners the highest quality and lowest-impact fiber available in today’s market, and we look forward to increasing our sustainability footprint thanks to our partnership with STORY3 Capital.”
For more information and to stay updated on Recover, visit www.Recovertex.com , or email hello@Recovertex.com .
About Recover:
Recover is a leading material sciences company and global producer of low-impact, high-performance recycled cotton fiber and cotton fiber blends. Its premium environmentally friendly, cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to close the loop on fashion. As a fourth-generation, family-owned company with a 70-year long history in the textile industry, Recover is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change makers to meet the industry’s sustainability targets. For more information, visit www.Recovertex.com and follow Recover on LinkedIn .
About STORY3:
STORY3 Capital is a leading alternative investment manager with deep experience in creating value within the consumer sector. STORY3 employs a flexible investment strategy and seeks to invest across the consumer value chain to deliver innovative investment solutions across market cycles. Paramount to its investment lens is a focus on companies at the nexus of consumer, commerce and content, where STORY3 believes its capital, skillset, and relationships can substantially impact value creation and investment returns. For more information, please visit www.story3capital.com .
(1) World Water Day – Call to action to address the global water scarcity problem
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005187/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom